Канеспор

Quick links

Choose a section

Quick links to important sections

Advertisements

Канеспор

Selected form

Advertisements
Advertisements

Treatment option: Hyperhidrosis

Advertisements

Overview of Канеспор

Quick Facts

Property Description
Active ingredient Bifonazole (INN)
Form Cream, Solution, Gel (for external use)
Pharmacological class Azole Antifungal Agent
Common use Local control of fungal skin infections
Origin Synthetic (Imidazole derivative)
Differentiating Feature Clinically recognized for once-daily application

Канеспор: Identity and Pharmacological Classification

Канеспор is a synthetic, single-component medicine intended exclusively for external use, classified as a broad-spectrum azole antifungal agent. The drug’s core efficacy is provided by the active substance, Bifonazole (INN), an established derivative of the imidazole chemical class. The product is typically positioned as a reliable local treatment for superficial fungal conditions.

Bifonazole is distinguished within the azole class by being clinically recognized for its increased fungicidal activity against dermatophytes, the primary cause of common fungal skin infections. This feature means the medication actively works to kill the fungi, providing a robust approach to eliminating the infection source.

Composition, Form, and General Purpose

The pharmaceutical identity of Канеспор is defined by the delivery of Bifonazole, typically at a 10 mg/g concentration, via preparations adapted for topical application. It is available in common forms such as a cream, a solution, or a gel, which employ specific bases to facilitate effective permeation into the superficial skin layers.

The general therapeutic purpose of Канеспор is the elimination and control of fungal mycoses localized to the skin's surface, such as athlete's foot. Bifonazole offers the convenience of once-daily application, a practical benefit directly linked to the drug's effective and sustained concentration within the skin. This dual action ensures a wide-ranging antimycotic effect against dermatophytes, yeasts, and moulds.

Advertisements

What side effects are possible with Канеспор?

The safety profile of topical Bifonazole (Канеспор) is primarily characterized by localized reactions, with most documented effects confined to the area of application due to low systemic absorption. These effects are formally classified in regulatory documents according to frequency and System-Organ Class (SOC).

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Very Common Skin burning sensation at the application site.
Uncommon Erythema (redness), Pruritus (itching), skin irritation, Eczema, and localized Oedema (swelling).
Frequency Not Known Administration site pain, Allergic dermatitis, Rash, Urticaria (hives), Blister, Skin exfoliation, and Systemic hypersensitivity reactions.

The majority of these are classified under Skin and Subcutaneous Tissue Disorders or General Disorders at the Administration Site. These localized effects are generally documented as reversible upon discontinuation of the medicine.

Safety Considerations and Restrictions

Regulatory documents highlight specific constraints for use. The medicine is not recommended during the first trimester of pregnancy and use during lactation should be avoided, particularly on the chest area. Use in infants and neonates requires medical supervision.

A high-level safety note advises that concomitant use with the oral anticoagulant Warfarin may require monitoring of the INR (anticoagulant status) due to potential safety consequences. Furthermore, the product is not intended for ophthalmic use and caution is required in patients with a history of hypersensitivity to other imidazole antifungal agents.

Advertisements

Overdose and Emergency Response

Official Regulatory Information on Overdose

The official regulatory profile for topical Bifonazole (Канеспор) establishes a low risk of systemic harm from overuse. Acute intoxication is not anticipated following a single, extensive application to the skin.

The primary overdose scenario addressed in official documentation is inadvertent oral ingestion.

Overdose Risk and Manifestations Official Documentation Statement
Risk from Topical Use No risk of acute intoxication is anticipated from a single dermal overdose.
Symptoms from Ingestion Accidental oral ingestion may lead to the appearance of clinical symptoms, specifically dizziness, nausea, or vomiting.
Life-Threatening Outcomes No specific severe or life-threatening systemic outcomes are explicitly documented in the official regulatory sections.

When to Seek Immediate Medical Help

The requirement to seek urgent medical attention is mandated by regulatory authorities in the event of accidental oral ingestion. If oral ingestion occurs and the specific clinical symptoms of overdose (dizziness, nausea, or vomiting) become apparent, immediate medical help is required.

Official Procedural Note: In such symptomatic cases, a procedure such as gastric lavage may be considered, but this intervention is conditional. Gastric lavage should only be performed if the patient is symptomatic and provided that the airway can be protected adequately. No specific antidote is mentioned in the official labeling for Bifonazole overdose.

Advertisements

Therapeutic Uses of Канеспор

What Канеспор Treats: Main Uses and Benefits

Канеспор is generally used for managing dermatological conditions characterized by periods of heightened symptoms. The medicine is relevant when supportive symptom management is appropriate for conditions caused by fungal infections.

This medication is applied across domains where additional symptomatic support is needed for conditions such as athlete’s foot (Tinea pedis), ringworm (Tinea corporis), jock itch (Tinea cruris), as well as superficial candidiasis and pityriasis versicolor. It helps address symptom clusters that may become intense or disruptive, including itching, burning, and scaling.

It provides support that helps ease the overall burden of symptoms that interfere with daily functioning. The medicine assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Symptom Support
The medication may assist with localized discomfort and helps improve day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information on Clotrimazole
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Status and Restrictions

The eligibility for using Канеспор (Bifonazole) is defined by regulatory guidelines that detail specific populations who must not use the medicine and others who require medical oversight.

Category Official Regulatory Status (Label-Based)
Absolute Contraindication Patients with known hypersensitivity to bifonazole or to other imidazole antifungal agents (e.g., clotrimazole) must not use the medicine.
Pediatric Restriction Infants and young children (e.g., 28 days to 23 months) are only eligible for use under medical supervision; the treatment of infants with nappy rash is contraindicated.
Pregnancy/Lactation Pregnancy: Use is not recommended in the first trimester; must only be used after a doctor has evaluated potential risk. Lactation: Use is not recommended; the product must not be applied to the chest area during breastfeeding.
Standard Eligibility Adults and older children/adolescents are generally eligible for standard labeled use.

These official statements structure the eligibility profile, formally excluding populations with documented allergies or specific localized conditions. For vulnerable groups such as infants and pregnant or breastfeeding women, the regulatory status dictates restricted use or complete prohibition, ensuring adherence to label-based population safety standards.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for topical preparations of Канеспор (Bifonazole) indicates a very limited potential for systemic drug interactions due to the active substance's low absorption through the skin.

Documented Interaction

Product Category Interacting Medicines Interaction Statement
Anticoagulants (Coumarin Type) Warfarin and other coumarin derivatives Limited data suggest a possible interaction, resulting in an increase in the anticoagulant effect (elevated INR).

Interaction Management and Monitoring

This interaction imposes a specific procedural requirement for patient management. When topical Bifonazole is used in a patient concurrently taking an anticoagulant, caution must be exercised, and the anticoagulant effect should be appropriately monitored (e.g., periodic INR testing).

Closer monitoring of the International Normalized Ratio (INR) may be required when the product is applied under conditions that can increase systemic exposure. These conditions include application to large surface areas, broken or damaged skin, or application under occlusion (e.g., dressings).

General Interaction Profile

No other drug-drug, food, alcohol, or herbal product interactions are officially documented in regulatory labeling for topical Bifonazole. The interaction profile is strictly defined by the need to manage the risk of increased anticoagulant activity in patients taking coumarin derivatives.

Advertisements

Mechanism of Action

Dual-Targeted Interference with Cell Membrane Sterol Synthesis

This drug acts by engaging two different enzyme targets within the essential ergosterol biosynthesis pathway of the cell. Specifically, it functions as a non-competitive enzyme inhibitor, blocking both lanosterol 14alpha-demethylase and a related enzyme involved in sterol synthesis. This dual-target inhibition prevents the proper formation of essential sterol components required for the cell's outer layer, which is a process that leads to impaired structural integrity.

Mechanistic Cascade of Structural Impairment

The mechanism initiates a molecular cascade where the inadequate production of ergosterol combines with the accumulation of toxic intermediate sterols inside the cell. This dual stress critically impairs cell membrane function, resulting in the loss of crucial barrier integrity. The consequence of this structural damage is the uncontrolled outflow of cellular contents, culminating in the final physiological event of cell lysis and the complete destruction of the targeted cell population.

Advertisements

Dosage and Administration Information

The administration of Канеспор is defined as a topical, cutaneous application. The medicine is only intended for use on the skin and is applied once daily, typically in the evening before retiring, to maintain sustained contact time. The standard regimen for adults involves applying a thin layer of the 1% cream to the affected area. For dosing, a small quantity, often compared to the size of a pea, is generally sufficient to cover a region the size of an adult palm.

Proper application requires the affected skin to be washed and dried thoroughly before the cream is gently rubbed in. The application site must not be covered with occlusive bandages or dressings. Should an application be missed, the next dose should be applied as soon as it is remembered, but the patient must never double the dose to compensate for the missed application.

The duration of use is fixed and varies based on the specific infection being treated, but the full course must be completed, even if the symptoms appear to resolve early. For example, the course for Tinea pedis is typically three weeks, while treatment for Pityriasis versicolor is generally two weeks. An important administration rule is that the use of this cream in infants and children must be carried out under medical supervision.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Канеспор

Evidence for use in Fungal Skin Infections (Dermatophytoses)

A large body of research, including numerous Randomized Controlled Trials (RCTs), was studied to examine Bifonazole's use against common fungal skin infections, such as athlete’s foot (Tinea pedis) and ringworm (Tinea corporis). These studies explored short-term symptom changes in adults who had mycologically confirmed infections. Researchers specifically monitored both Mycological Cure (the absence of fungal growth confirmed in the laboratory) and Clinical Cure (the measurement of visible signs like scaling and redness), as well as changes in patient-reported outcomes describing perceived discomfort.

Studies monitored the measurement of the absence of fungal growth in the laboratory over defined time intervals. When trials compared the medicine against a placebo or no treatment, the pooled research examined how Mycological Cure was measured at the end of treatment. Evidence quality varies across studies, with definitive, long-term data on sustained outcomes or relapse rates for individual treatments often being limited.


Evidence for use in Superficial Yeast and Mould Infections

Research has also explored the use of Bifonazole for superficial yeast and mould infections, including Cutaneous Candidiasis and Pityriasis Versicolor. The evidence base includes a large synopsis of clinical trials. Studies were conducted during periods of increased symptom activity and focused on episodes where symptoms become more noticeable. The outcomes related to physical discomfort and the measurement of overall response rate (combining clinical and mycological findings) were monitored.

Studies reported measurements of the absence of fungal growth (Mycological Cure) and the evolution of physical signs within the short-term observation window. Trials exploring the azole class, in which the medicine is included, examined how the outcome of Mycological Cure was measured when compared to a placebo. This research provides insight into short-term changes in these types of superficial mycoses.


Comparative Research and Trial Design

Many studies employed an active-control design, meaning the medicine was compared against other established topical antifungal agents. These comparisons were used to evaluate whether differences in Mycological Cure and Symptom Change were observed among different products. Research has explored whether the outcome of Mycological Cure at the end of treatment showed patterns of difference when comparing the medicine to various other topical antifungal drugs.

However, the comparative evidence is lacking for certain direct comparisons, requiring meta-analyses to combine direct and indirect evidence, which was observed in some studies to introduce inconsistency or heterogeneity into the overall findings.


Evidence in Specific Patient Populations and Gaps

Research examining the use of Bifonazole was primarily conducted in adults. Specific data for certain groups remain insufficient or limited. For children (infants, toddlers, and young children), evidence for its use is limited in the available clinical trial pool.

Similarly, for pregnant women, clinical data from the use of Bifonazole are unavailable for this population. While animal studies were conducted using high oral doses—which is not the route of administration for this cream—research monitored information on systemic absorption following topical application in humans. For breastfeeding populations, research does not fully establish whether the drug is excreted in human milk; however, data show patterns related to excretion in animals.

Key Studies & References

  1. Canespor 10 mg/g Part VI: Summary of the risk management plan (Regulatory document informing pregnancy/lactation and systemic exposure data)
  2. Health Products Regulatory Authority IPAR - Public Assessment Report (Consolidating non-clinical and clinical absorption data for safety/populations sections)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Канеспор (FAQ)


Q: What kind of infections is Канеспор typically used for?

A: According to official product information, Канеспор is primarily used to treat fungal skin infections. This includes those caused by dermatophytes (which cause conditions like ringworm and athlete's foot), as well as infections caused by yeasts (like Candida species) and moulds. Common conditions treated are athlete’s foot (tinea pedis), ringworm, and pityriasis versicolor.


Q: What are the benefits of using Канеспор compared to other athlete's foot treatments?

A: The active substance in Канеспор, Bifonazole, is an azole antifungal agent. A key feature noted in product information is the once-daily application schedule, which distinguishes it from some other topical antifungal treatments that may require more frequent application.


Q: Does Канеспор cure nail fungus completely?

A: The cream formulation of Канеспор is generally not intended for treating nail infections (onychomycosis) by itself. However, Bifonazole is the active ingredient used in specialized two-phase treatment sets for nail infections, which involve removing the infected nail parts before treatment begins.


Q: Can I buy Канеспор over the counter, or do I need a prescription?

A: Topical Bifonazole products, such as Канеспор cream, are commonly available without a prescription (over-the-counter) in many regulatory areas. Its over-the-counter status makes it readily available for consumers.


Q: Can children use Канеспор, and is the formulation the same as for adults?

A: The use of Канеспор in infants and young children requires medical supervision. The product is contraindicated (should not be used) for treating nappy rash. While the strength is generally the same as the adult product, use in young children requires approval and close supervision from a healthcare professional, as specified in the product label.


Q: Is Канеспор safe to use during pregnancy (general question, not personal advice)?

A: Official regulatory documents indicate that Канеспор is not recommended during the first trimester of pregnancy. For use during the later stages of pregnancy, it should only be used after a doctor has evaluated the potential benefit to the patient against any potential risk to the fetus.


Q: Why is Канеспор often recommended for treating tinea infections?

A: Канеспор is a broad-spectrum antifungal with confirmed fungicidal activity against dermatophytes, which cause tinea infections like athlete's foot. These properties, along with its once-daily application, contribute to its use in treating these types of infections.


Q: What is the recommended duration of treatment with Канеспор for different infections?

A: The official product information specifies a fixed duration that depends on the infection being treated. For example, athlete's foot usually requires two to three weeks of treatment. It is generally required that the full course be completed, even if visible symptoms appear to resolve earlier.


Q: Is Канеспор generally considered safe for people with sensitive skin?

A: Localized skin reactions like a burning sensation, redness, or itching are common side effects reported in clinical use. Furthermore, the cream contains inactive ingredients (excipients) such as cetostearyl alcohol, which may sometimes cause local skin irritation, like contact dermatitis.


Q: What if I accidentally swallow a small amount of Канеспор cream?

A: Regulatory information states that a single, inadvertent oral ingestion of a small amount of the cream is generally not expected to cause acute intoxication. However, if clinical symptoms of overdose such as dizziness, nausea, or vomiting occur, medical attention should be sought.


Q: Can I use Канеспор while swimming or showering?

A: The medicine is designed for once-daily application to clean, dry skin, typically applied in the evening. While no specific regulatory guidance is provided about immediate reapplication after swimming or showering, regulatory guidance for administration requires the affected area to be thoroughly dried before the cream is applied.


Q: How should I store Канеспор to keep it effective?

A: Official storage guidelines require the product to be stored at a temperature at or below 25 C (or 30 C depending on the region) in the original carton to protect it from light and moisture. The solution must also be kept away from open flame.


Q: Can heat or humidity affect how well Канеспор works?

A: Regulatory storage guidelines specify a required storage temperature (e.g., 25 C) to maintain the product's stability and effectiveness. While there are no explicit warnings about general environmental humidity during use, proper storage conditions are key to ensuring the medicine retains its full activity.


Q: Does Канеспор work against yeast infections (like Candida)?

A: Yes, according to its pharmacological classification, Канеспор (Bifonazole) is a broad-spectrum antifungal agent. This means it is active against a wide variety of fungi, including yeasts such as Candida species.


Q: What is the difference between Канеспор and treatments containing clotrimazole?

A: Both active ingredients, Bifonazole (in Канеспор) and clotrimazole, belong to the same antifungal drug class (imidazoles). A practical difference is that Bifonazole is clinically recognized for being effective when applied only once a day, whereas clotrimazole often requires multiple daily applications.


Q: Are there any known interactions between Канеспор and sun exposure?

A: Clinical reviews have noted that phototoxicity, which is an abnormal skin sensitivity to sunlight, has been reported as a rare side effect with topical Bifonazole. Patients should be cautious about sun exposure and may consider protective measures.


Q: Can Канеспор be used on broken or cracked skin?

A: The medicine is applied to the affected skin area. However, regulatory warnings advise caution when applying to large surface areas or to broken or damaged skin, as the risk of systemic absorption is increased, which is a particular concern if a patient is concurrently taking an oral anticoagulant like warfarin.


Q: Does using Канеспор make the skin more sensitive to anything else?

A: The cream formulation contains certain excipients, such as cetostearyl alcohol and benzyl alcohol. Official documents note that these substances may cause local allergic reactions or skin sensitivity (contact dermatitis) in some individuals.


Q: Can Канеспор be used for preventing fungal infections?

A: The regulatory indications for Канеспор specifically state its use for the treatment of existing fungal skin infections, such as ringworm and athlete's foot. The product label does not include a claim for preventing future infections (prophylaxis).


Q: Does alcohol or caffeine affect the use of Канеспор?

A: Official regulatory documentation for topical Канеспор indicates that there are no known interactions with food, alcohol, or caffeine. The only documented interaction is a caution required when used alongside coumarin anticoagulants (blood-thinners) such as warfarin.


Q: What does the term 'broad-spectrum antifungal' mean in relation to Канеспор?

A: This term is used to classify the drug's activity. It means that the active substance in Канеспор, Bifonazole, is effective against a wide range of different fungi, including common pathogens like dermatophytes, yeasts, and moulds.


Q: Is Канеспор effective against dermatophytes?

A: Yes, regulatory and clinical information confirms that Канеспор is effective against dermatophytes. These are the specific types of fungi that are the cause of common skin infections like athlete's foot and ringworm.

Advertisements

How should Канеспор be stored and disposed of?

Storage and Disposal of Canespor (Bifonazole)

Official regulatory documentation specifies requirements for the storage, stability, and disposal of Canespor.

Storage Requirement Condition
Temperature Store at or below 25 C (or 30 C depending on regulatory region).
Protection Store in the original carton to protect the product from light and moisture.
Child Safety Keep out of the sight and reach of children.
Handling The solution formulation must be kept away from open flame due to flammability.

Stability is limited, as the product must not be used after the expiry date. Once opened, the cream has a maximum in-use period of 6 or 16 months, depending on the pack size. For disposal, the medicine must not be thrown into wastewater or household waste. Users are directed to ask a pharmacist for the proper method of disposing of unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Канеспор found in:

A-Z Index: